Triple agonism (GLP-1 + GIP + glucagon) is a real mechanistic advance, not just marketing but the full implications, especially for muscle mass, aren't confirmed yet
This omission limits pharmacological context, hinders potency normalization across studies, and constrains the prioritization of peptide leads for translational development [177, 178]
In fact, up to 2.7% of people taking the drug experienced burping in clinical trials
The fact that most patients are diagnosed at advanced stages underscores the critical importance of early detection for the formulation of effective treatment strategies
Most patients start noticing weight loss within the first few weeks, with significant results appearing after a few months of consistent use
It *might* be covered if prescribed primarily for another FDA-approved, covered condition like OSA or potentially type 2 diabetes (if Mounjaro is used off-label, though that carries its own insurance hurdles)